Cyclodextrin-based gefitinib nanobubbles for synergistic apoptosis in lung cancer

References

• Wang YT, Pan SH, Tsai CF, et al. Phosphoproteomics reveals HMGA1, a CK2 Substrate, as a Drug-resistant target in non-small cell lung cancer. Sci Rep. 2017;7:44021.
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, et al. Epithelial growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181.
   PubMed Web of Science ®Google Scholar
• Recondo G, Facchinetti F, Olaussen KA, et al. Making the first move in EGFR-driven or ALK-driven NSCLC: first generation or next generation TKI? Nat Rev Clin Oncol. 2018;15(11):694–708.
   PubMed Web of Science ®Google Scholar
• Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–162.
   PubMed Web of Science ®Google Scholar
• Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415–1426.
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–967.
   PubMed Web of Science ®Google Scholar
• Stinchocombe TE, Socinski MA. Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance? Onchologist. 2008;13(9):933–944.
   PubMed Web of Science ®Google Scholar
• Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev: Drug Discov. 2009;8(9):709–723.
   PubMed Web of Science ®Google Scholar
• Weng CH, Chen LY, Lin YC, et al. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene. 2019;38(4):455–468.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010, CA. Cancer J Clin. 2010;60(5):277–300.
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183–232.
   PubMed Web of Science ®Google Scholar
• Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53:2379–2385.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):1–27.
   PubMedGoogle Scholar
• Targeting AC. HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003;30(3):3–14.
   Web of Science ®Google Scholar
• Janne PA. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. Semin Oncol. 2005;32(6):9–15.
   Web of Science ®Google Scholar
• Nurwidya F, Takahashi F, Takahashi K. Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation. J Nat Sci Biol Med. 2016;7(2):119–123.
   PubMedGoogle Scholar
• Bermudez JG, Baudrier L, La K, et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nat Cell Biol. 2018;20(7):775–781.
   PubMed Web of Science ®Google Scholar
• Henze AT, Garvalov BK, Seidel S, et al. Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR. Nat Commun. 2014;5:5582.
   PubMed Web of Science ®Google Scholar
• Goda N, Ryan HE, Khadivi B, et al. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol. 2003;23(1):359–369.
   PubMed Web of Science ®Google Scholar
• Durand RE, Raleigh JA. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res. 1998;58(16):3547–3550.
   PubMed Web of Science ®Google Scholar
• Webster L, Hodgkiss RJ, Wilson GD. Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo. Br J Cancer. 1998;77(2):227–234.
   PubMed Web of Science ®Google Scholar
• Shende P, Desai D, Gaud RS. Role of Solid-Gas interface of nanobubbles for therapeutic applications. Crit Rev Ther Drug Carrier Sys. 2018;35(5):469–494.
   PubMed Web of Science ®Google Scholar
• Bhandari PN, Cui Y, Elzey BD, et al. Oxygen nanobubbles revert hypoxia by methylation programming. Sci Rep. 2017;7(1):1–14.
   PubMedGoogle Scholar
• Hatfield SM, Kjaergaard J, Lukashev D, et al. Immunological mechanisms of the antitumor e ects of supplemental oxygenation. Sci Transl Med. 2015;7(277):277ra30.
   PubMed Web of Science ®Google Scholar
• Her YF, Nelson-Holte M, Maher LJ. Oxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma. PLOS One. 2015;10(5):e0127471.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Horsman MR. Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Ther. 2015;153:107–124.
   PubMed Web of Science ®Google Scholar
• Trotta F, Cavalli R, Martina K, et al. Cyclodextrin nanosponges as effective gas carriers. J Incl Phenom Macrocyclic Chem. 2011;71(1):189–194.
   Web of Science ®Google Scholar
• Trotta F, Zanetti M, Cavalli R. Beilstein, Cyclodextrin-based nanosponges as drug carriers. J Org Chem. 2012;8:2091–2099.
   Web of Science ®Google Scholar
• Cramer F, Henglein FM. Einschlussverbindungen der cyclodextrine mit gasen. Angew Chem. 1956;68(20):649.
   Google Scholar
• Wang JP, Zhou XL, Yan JP, et al. Nanobubbles as ultrasound contrast agent for facilitating small cell lung cancer imaging. Oncotarget. 2017;8(44):78153–78162.
   PubMedGoogle Scholar
• Zhang J, Chen Y, Deng C, et al. The optimized fabrication of a novel nanobubble for tumor imaging. Front Pharmacol. 2019;10:610.
   PubMed Web of Science ®Google Scholar
• Song L, Guohao W, Xuandi H, et al. Biogenic nanobubbles for effective oxygen delivery and enhanced photodynamic therapy of cancer. Acta Biomater. 2020;108:313–325.
   PubMed Web of Science ®Google Scholar
• Wang JP, Yan JP, Xu J, et al. Paclitaxel-loaded nanobubble targeted to pro-gastrin-releasing peptide inhibits the growth of small cell lung cancer. Cancer Mang Res. 2019;11:6637.
   Web of Science ®Google Scholar
• Baspınar Y, Erel-Akbaba G, Kotmakç M, et al. Development and characterization of nanobubbles containing paclitaxel and survivin inhibitor YM155 against lung cancer. Int J Pharm. 2019;566:149–156.
   PubMed Web of Science ®Google Scholar
• Shende P, Trotta F, Gaud RS, et al. Influence of different techniques on formulation and comparative characterization of inclusion complexes of ASA with β-Cyclodextrin and inclusion complexes of ASA with PMDA cross-linked β-Cyclodextrin nanosponges. J Incl Phenom. 2012;74(1–4):447–454.
   Web of Science ®Google Scholar
• Desai D, Shende P. Drug-free cyclodextrin-based SP. Nanosponges for antimicrobial activity. J Pharm Innov. 2020;16 (2): 258-268.
   Web of Science ®Google Scholar
• Shende P, Kulkarni YA, Gaud RS, et al. Acute and repeated dose toxicity studies of different β-Cyclodextrin-based nanosponge formulations. J Pharm Sci. 2015;104(5):1856–1863.
   PubMed Web of Science ®Google Scholar
• Hengrui Z, Wen S, Zhang Y, et al. Polyethylene Glycol functionalized magnetic mesoporous silica nanoparticles as carriers for CpG Immunotherapy In vitro and In vivo. PLOS One. 2015;10(10):1–17.
   Web of Science ®Google Scholar
• Sadjadi S, Heravi M, Daraie M. Cyclodextrin nanosponges: a potential catalyst and catalyst support for synthesis of xanthenes. Res Chem Intermediat. 2016;43(2):1–15.
   Web of Science ®Google Scholar
• Shende PK, Gaud RS, Bakal R, et al. Effect of inclusion complexation of meloxicam with β-cyclodextrin-and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies. Colloids Surface B. 2015;136:105–110.
   PubMed Web of Science ®Google Scholar
• Stieger N, Liebenberg W, Wessels JC. UV spectrophotometric method for the identification and solubility determination of nevirapine. Pharmazie. 2009;64(10):690–691.
   PubMed Web of Science ®Google Scholar
• Zullino S, Argenziano M, Ansari S, et al. Superparamagnetic oxygen-loaded nanobubbles to enhance tumor oxygenation during hyperthermia. Front Pharmacol. 2019;10:1001.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Yu Z, Li J, et al. Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway. Oncol Lett. 2016;12(1):63–68.
   PubMed Web of Science ®Google Scholar
• Han W, Pan H, Chen Y, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PloS One. 2011;6(6):e18691.
   PubMed Web of Science ®Google Scholar
• Shende P, Patil S, Gaud RS. A combinatorial approach of inclusion complexation and dendrimer synthesization for effective targeting EGFR-TK. Mater Sci Eng C: Mater Biol Appl. 2017;76:959–965.
   PubMed Web of Science ®Google Scholar
• MDA S, Martínez-Monteagudo SI. Oxidative stability of fats and oils measured by differential scanning calorimetry for food and industrial applications. In: Appl calorim a wide context-differ scanning calorimetry, isothermal titration calorim microcalorim. mal Ali Elkordy, University of Sunderland, United Kingdom. IntechOpen. 2013: 445-474.
   Google Scholar
• Rahman AM, Korashy HM, Kassem MG. Academic Press. Gefitinib Profiles Drug Subst Excip Relat Methodol. 2014;39:239–264.
   PubMedGoogle Scholar
• Suk JS, Xu Q, Kim N, et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28–51.
   PubMed Web of Science ®Google Scholar
• Godugu C, Doddapaneni R, Patel AR, et al. Novel gefitinib formulation with improved oral bioavailability in treatment of A431 skin carcinoma. Pharma Res. 2016;33(1):137–154.
   Google Scholar
• Miranda JCD, Martins TEA, Veiga F, et al. Cyclodextrins and ternary complexes: technology to improve solubility of poorly soluble drugs. Braz J Pharm Sci. 2011;47(4):665–681.
   Web of Science ®Google Scholar
• Makoid MC, Dufour A, Banakar UV. Modelling of dissolution behaviour of controlled release system. STP pharma pratiques. 1993;3:49.
   Google Scholar
• Zheng W, Liu T, Sun R, et al. Daidzein induces choriocarcinoma cell apoptosis in a dose-dependent manner via the mitochondrial apoptotic pathway. Mol Med Rep. 2018;17(4):6093–6099.
   PubMed Web of Science ®Google Scholar
• Qian Y, Qiu M, Wu Q, et al. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles. Sci Rep. 2014;4(1):1–8.
   Google Scholar
• Akinc A, Battaglia G. Exploiting endocytosis for nanomedicines. Cold Spring Harbor Perspect Biol. 2013;5(11):a016980.
   PubMed Web of Science ®Google Scholar
• Zhou X, Shi K, Hao Y, et al. Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy. Asian Journal of Pharmaceutical Sciences. 2020;15(1):26–41.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ohh M. Oxygen‐mediated endocytosis in cancer. J Cell Mol Med. 2010;14(3):496–503.
   PubMed Web of Science ®Google Scholar